X1 Biotech Inc.

NEEDHAM, MA · Founded 2021 · CIK 0002068848 · Biotech · Private

Small-molecule RUNX1 inhibitor therapeutic (X101)

x1biotech.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$235K
3 Form D · Jun 2026
4 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raised· 1 of 2 same dayForm D · SEC$95,000
Private capital raised· 2 of 2 same dayForm D · SEC$100,000
Private capital raisedForm D · SEC$40,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2622MSM PROTEIN TECHNOLOGIES, INC—$250K
2623SNC THERAPEUTICS, INC.—$250K
2624Dome Therapeutics, LLC—$250K
2625X1 Biotech Inc.—$235K
2626ZYMTRONIX CATALYTIC SYSTEMS, INC.——
2627HUNTERIAN MEDICINE LLC—$230K
2628Daya CNS, LLC—$228K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 7 related persons
  • Michael AcetiExecutive Officer
  • Joseph Arboleda-ValasquezDirector
  • Joseph Arboleda-VelasquezDirector
  • Neal ChenDirector
  • Dean EliottDirector
  • Lawrence KaufmanExecutive Officer
  • Leo KimDirector

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.